R. Venkataramanan, A. Swaminathan, T. Prasad, A. Jain, S. Zuckerman et al., Clinical Pharmacokinetics of Tacrolimus, Clinical Pharmacokinetics, vol.29, issue.6, pp.404-434, 1995.
DOI : 10.2165/00003088-199529060-00003

D. Laskow, F. Vincenti, J. Neylan, R. Mendez, and A. Matas, AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATION, Transplantation, vol.62, issue.7, pp.900-905, 1996.
DOI : 10.1097/00007890-199610150-00005

P. Wallemacq, V. Armstrong, M. Brunet, V. Haufroid, D. Holt et al., Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Therapeutic Drug Monitoring, vol.31, issue.2, pp.139-52, 2009.
DOI : 10.1097/FTD.0b013e318198d092

M. Neely, M. Van-guilder, W. Yamada, A. Schumitzky, and R. Jelliffe, Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R, Therapeutic Drug Monitoring, vol.34, issue.4, pp.467-76, 2012.
DOI : 10.1097/FTD.0b013e31825c4ba6

C. Staatz, C. Willis, P. Taylor, and S. Tett, Population pharmacokinetics of tacrolimus in adult kidney transplant recipients, Clinical Pharmacology & Therapeutics, vol.72, issue.6, pp.660-669, 2002.
DOI : 10.1067/mcp.2002.129304

C. Staatz and S. Tett, Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients, Clinical Pharmacokinetics, vol.30, issue.2
DOI : 10.1007/s40262-015-0282-2

A. Gaber, R. Alloway, K. Bodziak, B. Kaplan, and S. Bunnapradist, Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT), Transplantation Journal, vol.96, issue.2, pp.191-198, 2013.
DOI : 10.1097/TP.0b013e3182962cc1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723088

R. Alloway, D. Eckhoff, W. Washburn, and L. Teperman, Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): Phase 2 trial of stable liver transplant recipients, Liver Transplantation, vol.25, issue.suppl 1, pp.564-75, 2014.
DOI : 10.1002/lt.23844

S. Tremblay, V. Nigro, J. Weinberg, E. Woodle, and R. Alloway, A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study, American Journal of Transplantation, vol.42, issue.Suppl 2, 2016.
DOI : 10.1111/tri.12674

F. Saint-marcoux, J. Woillard, C. Jurado, and P. Marquet, Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure, Therapeutic Drug Monitoring, vol.35, issue.3, pp.322-329, 2013.
DOI : 10.1097/FTD.0b013e318285e779
URL : https://hal.archives-ouvertes.fr/inserm-00925160

A. Prémaud, J. Debord, A. Rousseau, L. Meur, Y. Toupance et al., A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.23, issue.6, pp.837-884, 2005.
DOI : 10.2165/00003088-200544080-00005

F. Saint-marcoux, C. Knoop, J. Debord, P. Thiry, A. Rousseau et al., Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.21, issue.4, pp.1317-1345, 2005.
DOI : 10.2165/00003088-200544120-00010

F. Saint-marcoux, J. Debord, N. Undre, A. Rousseau, and P. Marquet, Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation, Therapeutic Drug Monitoring, vol.32, pp.129-164, 2010.
DOI : 10.1097/FTD.0b013e3181cc70db

M. Neely, P. M. Rushing, T. Fu, X. Van-guilder, M. Bayard et al., Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software, Therapeutic Drug Monitoring, vol.38, issue.3
DOI : 10.1097/FTD.0000000000000276

A. Bustad, D. Terziivanov, R. Leary, R. Port, A. Schumitzky et al., Parametric and Nonparametric Population Methods, Clinical Pharmacokinetics, vol.36, issue.4, pp.365-83, 2006.
DOI : 10.2165/00003088-200645040-00003

A. Prémaud, L. Weber, B. Tönshoff, V. Armstrong, M. Oellerich et al., Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches, Pharmacological Research, vol.63, issue.3, pp.216-240, 2011.
DOI : 10.1016/j.phrs.2010.10.017

J. Woillard, F. Saint-marcoux, C. Monchaud, R. Youdarène, L. Pouche et al., Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients, Pharmacological Research, vol.99
DOI : 10.1016/j.phrs.2015.07.012

J. Woillard, V. Lebreton, M. Neely, P. Turlure, S. Girault et al., Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients, British Journal of Clinical Pharmacology, vol.51, issue.4, pp.836-882, 2014.
DOI : 10.1111/bcp.12394
URL : https://hal.archives-ouvertes.fr/inserm-00965397

D. Koop, L. Bleyle, M. Munar, G. Cherala, and A. Uzri, Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry, Journal of Chromatography B, vol.926
DOI : 10.1016/j.jchromb.2013.02.035

D. Hesselink, R. Bouamar, L. Elens, R. Van-schaik, and T. Van-gelder, The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation, Clinical Pharmacokinetics, vol.364, issue.Suppl. 1, pp.123-162, 2014.
DOI : 10.1007/s40262-013-0120-3

. Median, b1, a2, b2 are the shape and scale of the two gamma functions, r is the fraction of dose absorbed following the first gamma function, *C0 is the model estimated trough level for a theoretical dose of 1000 mg (the real trough level can be calculated by dividing this value by 1000 and multiplying by the patient dose), FAIV is the estimated, absolute bioavailability factor with respect to the IV route and ? is the elimination parameter, Cmax (the maximum concentration) and Tmax (time of the maximum concentration) were estimated from the fitted pharmacokinetic profiles